← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Elysium Therapeutics, Inc.
Lyons, CO
$12,698,967
Total funding
4
Grants
Funding over time
peak $4.1M · FY2014–21$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,698,967 · 4
By mechanism
R44$6,452,268 · 2
R01$5,971,873 · 1
R43$274,826 · 1
Investigators at Elysium Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$2,841,799
R01 · FY2018 · DA
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$2,677,544
R01 · FY2020 · DA
Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance$1,541,693
R44 · FY2015 · DA
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$1,145,409
R44 · FY2015 · DA
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$990,284
R44 · FY2019 · DA
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$986,904
R44 · FY2017 · DA
Attack Major Source of Abused Opioids: Molecularly Deactivate Unused Rx Opioids$985,349
R44 · FY2018 · DA
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction$452,530
R01 · FY2021 · DA
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$355,366
R44 · FY2016 · DA
Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$224,826
R43 · FY2018 · DA
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$224,737
R44 · FY2014 · DA
Bio-Activated Opioid Drugs with Unprecedented Oral and Non-Oral Abuse-Resistance$217,526
R44 · FY2014 · DA
Novel Opioid Prodrugs with Oral Overdose Protection: Minimizing Cost-of-Goods$50,000
R43 · FY2018 · DA
Unprecedented Diversion-/Abuse-Resistance: Molecular Deactivation of Opioid Drugs$5,000
R44 · FY2015 · DA